Teva Pharma (TEVA) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Reports First Quarter 2015 Results
April 30, 2015 7:01 AM EDTRevenues of $5.0 billion, in line with the first quarter of 2014. Organic revenue growth of 8% excluding the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants. Non-GAAP operating income of $1.5 billion, an increase of 11% compared to the first quarter of 2014. GAAP operating income of $749 million, down 23%. Non-GAAP net income of $1.2 billion, up 11%. GAAP net income of $446 million, a decrease of 40%. Non-GAAP diluted EPS of $1.36, an increase of 11%. GAAP diluted EPS of $0.52, a decrease of 40%.... More
